Selective LMP7 inhibition has been suggested as a therapeutic modality in autoimmune diseases, such as rheumatoid arthritis, since it induces an anti‐inflammatory response at lower doses than nonselective inhibitors, such as bortezomib, and reduces serum autoantibody levels, blocking disease progression.47 This evidence concerns the gene PSMB8 and autoimmune disease.